Skip to main content

Table 3 Cross tabulation of disorders, size of sample, source of support, pharmaceutical agents and outcome of papers with Jadad Index above 2

From: Off-label indications for atypical antipsychotics: A systematic review

Jadad Index > 2 (N = 10)

       
 

N of papers

Year

Jadad Index

P N W

N of patients

Financial support

Drug dose (mg/day)

Risperidone (N = 7)

       

Substance abuse

1

2000

3

0 1 0

125

I

2–8

OCD

1

2000

5

1 0 0

36

I

2.2

Pervasive Developmental disorder

3

1998, 2001, 2001

5, 3, 3

3 0 0

31, 38, 13

I, P, P

2.9, 2.9, 1.2

Stuttering

1

1999

3

1 0 0

21

I

<2

Tourette's syndrome

1

2001

5

1 0 0

50

P

3.8

Olanzapine (N = 3)

       

Depression

1

2001

3

1 0 0

28

P

12.5–13.5

Personality disorder

1

2001

5

1 0 0

28

P

5.33

Post Traumatic Stress disorder

1

2001

3

0 1 0

15

P

14.1

Quetiepine (N = 0)

0

-

-

-

-

-

-

  1. P = improvement of the patients, N = no change, W = worsening of the patients I: supported by State or independent grants P: supported by a pharmaceutical company